In order to develop an in vitro SKBR-3 model of acquired trastuzumab resistance, SKBR-3 which is HER-2 overexpressed breast cancer cell line was continuously exposed to 5 μg/ml trastuzumab for 6 months until cells had acquired trastuzumab resistance [25]. This evidence concerns the gene ERBB2 and breast cancer.